Division of Oncology, Department of Medicine, Seoul St. Mary's Hospital, Catholic University School of Medicine, Korea.
APMIS. 2012 Jan;120(1):28-38. doi: 10.1111/j.1600-0463.2011.02788.x. Epub 2011 Nov 11.
Integrin β(1) mediates cellular adhesion to the extracellular matrix (ECM) and is correlated with highly invasive and metastatic behavior in small cell lung cancer (SCLC). E-cadherin (ECAD) is a calcium-dependent cell-cell adhesion receptor that restricts invasion of cells and reduces metastasis. Rac1 is involved in the regulation of the actin cytoskeleton, adhesion, migration, invasion, and tumor metastasis. The aim of this study was to examine integrin β(1) , ECAD and rac1 expression in SCLC and to analyze the prognostic value of these markers in patients with SCLC. We analyzed integrin β(1) , ECAD, and rac1 expression in 112 SCLC tissues by immunohistochemical staining. Correlative analyses between integrin β(1) , ECAD, and rac1 expression and cliniopathological factors were performed. A total of 65 patients had extensive disease (ED) (58%), and 47 had limited disease (LD) (42%). The median follow-up duration was 61 months (range: 14-117 months), and the median progression free survival (PFS) and overall survival (OS) were 6.1 months (range: 4.8-7.4 months) and 9.7 months (range: 8.1-11.3 months), respectively. The expression of integrin β(1) , ECAD, and rac1 protein was observed in 64, 73, and 99 of SCLC tissues, respectively. The correlative analyses between integrin β(1) , ECAD, or rac1 expression and various clinical parameters did not show any statistical significance. However, the ECAD expression was associated with OS in the entire cohort. In contrast, the expression of integrin β(1) and rac1 was not associated with PFS or OS. In a subgroup analysis, patients with less than two metastasis had significantly longer OS (p = 0.047) if their tumors expressed integrin β(1) compared to those without integrin β(1) expression. In addition, OS was longer for patients with ECAD positive tumors compared to those whose tumors did not express ECAD in males (p = 0.032) and patients who never smoked (p < 0.001). Multivariate analysis showed that LD (p = 0.004), overall response rate (p = 0.003), and expression of ECAD (p = 0.015) were the independent good prognostic factors for OS. LD (p = 0.024), overall response rate (p < 0.001), and less than two metastasis (p = 0.003) were prognostic factors for longer PFS. These results suggest that ECAD expression may be useful as a prognostic indicator in patients with SCLC.
整合素 β(1)介导细胞与细胞外基质 (ECM) 的黏附,与小细胞肺癌 (SCLC) 的高侵袭性和转移性行为相关。E-钙黏蛋白 (ECAD) 是一种钙离子依赖性细胞-细胞黏附受体,限制细胞侵袭并减少转移。Rac1 参与肌动蛋白细胞骨架的调节、黏附、迁移、侵袭和肿瘤转移。本研究旨在检测 SCLC 中整合素 β(1)、ECAD 和 rac1 的表达,并分析这些标志物在 SCLC 患者中的预后价值。我们通过免疫组织化学染色分析了 112 例 SCLC 组织中整合素 β(1)、ECAD 和 rac1 的表达。对整合素 β(1)、ECAD 和 rac1 表达与临床病理因素之间的相关性进行了分析。共有 65 例患者为广泛期疾病 (ED) (58%),47 例为局限期疾病 (LD) (42%)。中位随访时间为 61 个月 (范围:14-117 个月),中位无进展生存期 (PFS) 和总生存期 (OS) 分别为 6.1 个月 (范围:4.8-7.4 个月) 和 9.7 个月 (范围:8.1-11.3 个月)。在 SCLC 组织中,分别观察到整合素 β(1)、ECAD 和 rac1 蛋白的表达 64、73 和 99 例。整合素 β(1)、ECAD 或 rac1 表达与各种临床参数之间的相关性分析未显示任何统计学意义。然而,ECAD 表达与整个队列的 OS 相关。相反,整合素 β(1)和 rac1 的表达与 PFS 或 OS 无关。在亚组分析中,与无整合素 β(1)表达的肿瘤相比,整合素 β(1)表达较少的肿瘤患者的 OS 明显更长 (p = 0.047)。此外,与肿瘤不表达 ECAD 的男性患者相比 (p = 0.032) 和从不吸烟的患者相比 (p < 0.001),ECAD 阳性肿瘤患者的 OS 更长。多变量分析显示,LD (p = 0.004)、总缓解率 (p = 0.003) 和 ECAD 表达 (p = 0.015) 是 OS 的独立预后良好因素。LD (p = 0.024)、总缓解率 (p < 0.001) 和少于两个转移 (p = 0.003) 是 PFS 更长的预后因素。这些结果表明,ECAD 表达可能是 SCLC 患者的有用预后指标。